Contraindication to Antiplatelet Rx for ~18 Percent With PCI

This article originally appeared here.
Share this content:
Contraindication to Antiplatelet Rx for ~18 Percent With PCI
Contraindication to Antiplatelet Rx for ~18 Percent With PCI

FRIDAY, June 3, 2016 (HealthDay News) -- About 18 percent of patients undergoing percutaneous coronary intervention (PCI) have a contraindication to commonly used antiplatelet medications, according to a study published online May 31 in Circulation: Cardiovascular Quality and Outcomes.

Geoffrey D. Barnes, M.D., from the Ann Arbor VA Medical Center in Michigan, and colleagues evaluated patients with contraindications to commonly used antiplatelet medications during and after PCI. The authors used national Veterans Affairs Clinical Assessment, Reporting, and Tracking program data for all PCIs performed between 2007 and 2013. They examined the correlation between contraindicated medications and outcomes of periprocedural bleeding and 30-day mortality.

The researchers found that 17.6 percent of the 64,294 patients undergoing PCI had a contraindication to a common antiplatelet medication, and 6.5 percent of these patients received a contraindicated medication. Any contraindicated medication use correlated with increased bleeding and 30-day mortality in unadjusted-analyses. After adjustment, significant correlations persisted for contraindicated abciximab use in patients with thrombocytopenia (hazard ratio, 2.23) and in patients with a previous stroke (hazard ratio, 1.93). In adjusted models there was no significant correlation noted for contraindicated abciximab use with 30-day mortality. In dialysis patients, eptifibatide use was not associated with an increased risk of bleeding or mortality.

"Approximately 6 percent of those patients received a contraindicated medication with attendant bleeding risk, although this did not translate into significantly higher risk of 30-day mortality," the authors write.

Two authors disclosed financial ties to the pharmaceutical, medical device, and health insurance industries.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters


More in Home

FDA Approves First Drug for Rare Form of Rickets

FDA Approves First Drug for Rare Form of ...

Crysvita approved for adults and children ages 1 year and older with x-linked hypophosphatemia

High FGF-23 Linked to Recurrent Cardiac Events After ACS

High FGF-23 Linked to Recurrent Cardiac Events After ...

FGF-23 in top quartile independently linked to greater risk of CV death, heart failure hospitalization

Medical Cannabis Not Recommended for Sleep Apnea

Medical Cannabis Not Recommended for Sleep Apnea

American Academy of Sleep Medicine says evidence insufficient to recommend cannabis for apnea

is free, fast, and customized just for you!

Already a member?

Sign In Now »